Tumor Treating Fields therapy could potentiate immunotherapy in non-small-cell lung cancer
- PMID: 37657465
- DOI: 10.1016/S1470-2045(23)00394-7
Tumor Treating Fields therapy could potentiate immunotherapy in non-small-cell lung cancer
Conflict of interest statement
I have received grants or had contracts with RS Oncology, Bayer, Astex Therapeutics, MSD, Roche, Eli Lilly, BMS, Boehringer Ingelheim; received consulting fees from RS Oncology, MSD, Boehringer Ingelheim; received fees for a speakers bureau for BMS; received payment for expert testimony from Leigh Day; received support for attending meetings from RS Oncology; and participated on an AstraZeneca advisory board. My institution received drugs for research from RS Oncology.
Comment on
-
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.Lancet Oncol. 2023 Sep;24(9):1002-1017. doi: 10.1016/S1470-2045(23)00344-3. Lancet Oncol. 2023. PMID: 37657460 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical